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Endocrine disorders are more common and appear earlier in people with trisomy 21 (T21) than in the general population, with
thyroid dysfunction being the most common, including both congenital and acquired hypothyroidism. The treatment for
biotinidase deﬁciency, a condition that occurs in approximately 1 : 110,000 people, is with biotin (vitamin B7) supplementation.
However, biotin can interfere with endocrine laboratory assays and cause falsely low thyroid-stimulating hormone (TSH) and
elevated free thyroxine (FT4) levels. This can interfere with the timely diagnosis and subsequent treatment of congenital hypothyroidism (CH). This case report describes an infant with partial biotinidase deﬁciency that was conﬁrmed on day 10 of life.
Routine screening erroneously reported “normal” TSH that caused delayed diagnosis of CH due to interference with the TSH
assay from concurrent biotin use. Once the biotin treatment was withheld for 4 days and the thyroid function tests repeated, an
elevated TSH became apparent. Treatment with tablet levothyroxine (L-T4) was started and subsequently changed to L-T4 oral
solution (Tirosint -SOL) to overcome treatment administration diﬃculties encountered with the tablet form. This resulted in
improved TSH control due to more accurate and consistent dosing compared with the tablet formulation. This is the ﬁrst report of
the use of L-T4 oral solution in an infant with T21 and biotinidase deﬁciency.
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1. Introduction
Trisomy 21 (T21), or Down syndrome, aﬀects both the
physical and intellectual development of the individual
[1, 2]. Endocrine disorders are more common and appear
earlier in people with T21 than in the general population [3].
Of the many endocrine disorders associated with T21,
thyroid dysfunction is the most common and includes both
congenital and acquired hypothyroidism [3–6]. Biotinidase
deﬁciency is a relatively rare condition occurring in approximately 1 : 110,000 [7]. Biotin (vitamin B7) supplementation is the treatment in biotinidase deﬁciency but can
interfere with many laboratory assays [8], causing falsely low
levels of thyroid-stimulating hormone (TSH) and elevated
free thyroxine (FT4) levels [9]. This can interfere with the
timely diagnosis of congenital hypothyroidism (CH) [10].
Levothyroxine (L-T4), in tablet form, is considered the
standard of care for treatment of hypothyroidism [11].

The therapeutic administration of tablet L-T4 in patients
with T21 may prove challenging due to the often-associated
occurrence of global developmental delay [2] and gastrointestinal problems, including functional and anatomical
anomalies [1]. There is a paucity of literature about concomitant CH and biotinidase deﬁciency, and no prior literature describing the use of levothyroxine sodium oral
solution (L-T4 oral solution), Tirosint -SOL, which has
recently become available in the United States for the
treatment of hypothyroidism [12]. Prior European studies
on the use of L-T4 oral solution in CH have shown initial
improvements in TSH and/or maintenance of euthyroidism
over time versus tablets [13–15]. These observations may be
linked to higher absorption and bioequivalence for liquid
L-T4 solution compared with tablets [13–15].
This case report describes a patient with “normal” TSH
on routine screening that caused delayed diagnosis of CH
due to interference with the TSH assay from concurrent
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biotin use. Once biotin treatment was withheld for 4 days
and thyroid function tests repeated, an elevated TSH became
apparent and CH was diagnosed. Treatment with tablet L-T4
was started and subsequently changed to L-T4 oral solution
to overcome administration diﬃculties. This resulted in
easier administration, accurate dosing, improved compliance, and biochemical euthyroidism.

2. Case Presentation
The patient is a white, non-Hispanic, full-term, infant female
with T21. Pertinent family history includes both parents
being conﬁrmed carriers for biotinidase deﬁciency. TSHbased newborn screening was performed and not ﬂagged as
abnormal for hypothyroidism. The patient was conﬁrmed
with partial biotinidase deﬁciency (2.0 U/L; reference range:
3.5–13.8 U/L) on day of life 10 and started on biotin 1000 µg
daily. At 2 weeks of life (WOL), thyroid function was tested
while receiving biotin: TSH was 3.39 mIU/mL and FT4 was
elevated at 5 ng/dL. Autoimmune evaluations for hyperthyroidism in the mother and child were negative. At 3
WOL, biotin was withheld for 3 days and repeat thyroid
function tests showed a TSH of 5.1 mIU/mL and that FT4
had normalized to 2.4 mIU/mL. At 8 WOL, after biotin was
withheld for 4 days, TSH was now elevated and FT4
remained in the reference range. Congenital hypothyroidism
was diagnosed at that time and the child was started on the
tablet form of L-T4 25 µg. The patient’s parents reported
diﬃculty in administering the dose via a crushed tablet in a
bottle of formula. At 16 WOL, biotin was withheld for 4 days
and repeat thyroid function tests showed that TSH was
suppressed and FT4 was slightly elevated. The dose of L-T4
was reduced to 12.5 µg (half tablet) and at 20 WOL, after
biotin was withheld for 4 days, repeat thyroid testing again
showed suppressed TSH and elevated FT4. The parents still
reported diﬃculty with cutting and crushing the L-T4 tablet,
resulting in inconsistent dosing. A referral to pediatric
endocrine care was then initiated and the L-T4 tablet formulation was changed to oral solution 13 µg daily. The
parents reported that administration was much easier with
the oral formulation. At 24 WOL, biotin was again withheld
for 4 days and repeat thyroid function tests showed normalization in both TSH (1.75 mIU/mL) and FT4 (1.96 ng/
dL). At 28 WOL, after biotin was withheld for 4 days, both
TSH and FT4 were still normal and the family reported
being very happy with the L-T4 oral solution. A timeline of
treatments administered along with outcomes is shown in
Table 1 and Figure 1.

3. Discussion
The prognosis for children with CH has improved signiﬁcantly due to the implementation of neonatal screening
methods and a more focused therapeutic approach [16].
Studies on cognitive function in patients with CH treated
soon after birth have shown that normal development can be
achieved in most patients, although cognitive development
depends on the severity of the disorder and the age at which
the hormone replacement therapy with L-T4 is started
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[16, 17]. Most neonatal screening methods in the United
States use a combination of TSH, FT4, or both [18].
Biotinidase deﬁciency, the major cause of late-onset
biotin-responsive multiple carboxylase deﬁciency, is an
autosomal recessive neurocutaneous disorder [7]. The
symptoms of biotinidase deﬁciency can be successfully
treated or prevented by administering pharmacological
doses of biotin [7], a water-soluble vitamin used widely as a
dietary supplement. In children with biotinidase deﬁciency,
doses are considerably higher (5-10 mg per kilogram of body
weight per day) [7] than the normal dietary reference intake
for children (5–25 μg per kilogram per day) [19]. Biotin has
been shown to interfere with many endocrine laboratory
assays (including TSH and FT4) [8, 9], which can lead to
erroneous or delayed diagnosis of CH. Prior literature has
described cases of children receiving an inaccurate diagnosis
of hyperthyroidism due to interference with the thyroid
function assay from high doses of biotin being given as a
therapy for metabolic disease [9, 10]. Our patient with
biotinidase deﬁciency had erroneous thyroid function
testing that was suggestive of hyperthyroidism. However,
once biotin supplementation was withheld, a true diagnosis
of CH was possible.
Thyroid hormones are pivotal for normal physical and
neuromotor development during the ﬁrst years of life.
Compliance with L-T4 treatment is one of the main factors
that inﬂuence the outcome of patients with CH [20]. The
therapeutic use of biotin in this infant resulted in false TSH
assay measurements so that they appeared in the normal
range and delayed the diagnosis of CH. Once the correct
diagnosis was made and treatment initiated, the TSH and
FT4 levels still remained outside the reference range because
of the suboptimal administration of tablet-formulated L-T4,
which should have been given in crushed form via a syringe,
but instead was being mixed with infant formula. However,
changing to L-T4 oral solution improved the ease and
consistency of administration and compliance with therapy,
and TSH levels subsequently improved.
T21 may cause additional challenges in infants and
young children receiving L-T4 treatment due to associated
gastrointestinal problems, feeding diﬃculties, and developmental delays [1]. In addition to the obvious advantage of
administering an oral solution instead of a crushed tablet to
an infant, L-T4 oral solution has many advantages for this
patient population: it has a sweet taste; contains only levothyroxine, glycerol, and water [12]; is free from additional
excipients; and does not require a gastric phase of dissolution (before absorption), meaning that it is more readily
absorbed than tablets [21]. Compared with the tablet form of
LT-4, faster achievement of target TSH values was demonstrated for the oral form and it also allows for easier
individualization of the dose [22]. As accurate dosing of
L-T4, both at initiation and in the long term, has been
recognized as a major challenge in the treatment of CH [22],
this case demonstrates the utility of L-T4 oral solution in
enabling ease of administration, accurate dosing, and subsequent TSH control in a patient with CH and T21.
In conclusion, this case demonstrates the eﬀectiveness of
using L-T4 oral solution to treat a patient with CH and T21.
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Table 1: Thyroid function tests after diagnosis of biotinidase deﬁciency.
Weeks of life
2
3
8
8.5
16

0
3
4

20

3

24
28

4
4

∗

TSH (mIU/mL)
FT4 (ng/dL)
Normal range∗
Measured
Normal range∗
0.71–9.34
5.0
0.7–2.4
0.71–9.34
2.4
0.7–2.4
0.35–5.5
1.6
0.8–1.9
Patient started on tablet L-T4 25 µg
0.08
0.35–5.5
2.2
0.8–1.9
Dose of tablet L-T4 reduced to 12.5 µg
0.04
0.35–5.5
2.4
0.8–1.9
Formulation of L-T4 changed to L-T4 oral solution 13 µg daily
1.75
0.35–5.5
1.96
0.8–1.9
3.2
0.35–5.5
0.8–1.9

Days oﬀ biotin

Measured
3.39
5.1
12.9
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Normal ranges shown are those used by the author’s institution. FT4, free thyroxine; L-T4, levothyroxine; TSH, thyroid-stimulating hormone.
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TSH (mIU/mL) and FT4 (ng/dL)

12
11
10
9
8
7
6
5
4
3
2
1
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
WOL 8.5
WOL 16
WOL 20
Tablet L-T425µg
Tablet L-T4 Formulation of L-T4 changed to
initiated
reduced
L-T4 oral solution 13 µg daily
to 12.5µg
Weeks of life (WOL)
TSH (mIU/mL) measured
TSH normal range∗:
WOL 2-3: 0.71 – 9.34 (mIU/mL)
WOL 8-28: 0.35 – 5.5 (mIU/mL)
FT4 (ng/dL) measured
FT4 normal range∗:
WOL 2-3: 0.7 – 2.4 (ng/dL)
WOL 8-28: 0.8 – 1.9 (ng/dL)

Figure 1: Thyroid-stimulating hormone (TSH) and free thyroxine (FT4) timeline. ∗ Normal ranges shown are those used by the author’s
institution. L-T4, levothyroxine sodium oral solution; WOL, weeks of life.
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The use of L-T4 oral solution (Tirosint -SOL) may improve
compliance and consistency of thyroid control in pediatric
patients, especially in patients with T21 with/or without CH
who have special needs. Also, clinicians should be aware that
infants receiving biotin supplementation for biotinidase
deﬁciency will need this therapy to be withheld before
screening for CH. Failure to do so can result in erroneous

measurement of thyroid levels and delayed diagnosis and
treatment of CH.
A limitation of this case report is that we report on a
single subject who was followed for a short time. However,
this case provides point-of-care evidence that could help to
inform practice guidelines and provide practical medical
education to other healthcare professionals.
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Data Availability
Additional information pertaining to this case may be
requested by contacting the corresponding author.
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